首页> 外文期刊>Toxicology: An International Journal Concerned with the Effects of Chemicals on Living Systems >Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.
【24h】

Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.

机译:确定选定的治疗剂作为羧酸酯酶1的抑制剂:代谢药物相互作用的潜在来源。

获取原文
获取原文并翻译 | 示例
           

摘要

A series of studies were designed and carried out in order to explore the potential for the major human hepatic hydrolase, carboxylesterase 1 (hCES1), to serve as a target of metabolic inhibition by a variety of medications. The risk of adverse drug-drug interaction(s) is present when metabolic inhibitors are combined with known or suspected substrates of a given enzyme. In the present report the abundantly expressed hepatic enzyme, hCES1, was examined as a potential target of metabolic inhibition by a number of routinely prescribed medications. hCES1 has been seldom assessed in this regard despite its role in the metabolism and detoxification of many compounds. The psychostimulant methylphenidate (MPH) was chosen as an hCES1 selective substrate. In vitro studies were performed using previously developed cell lines which overexpress hCES1 with both p-nitrophenyl acetate and d-MPH serving as known substrates. Aripiprazole, perphenazine, thioridazine, and fluoxetine were determined to be the potent hCES1 inhibitors. A complementary animal study followed in vitro screening studies to further evaluate the inhibitory effect of aripiprazole on CES1 activity in FVB mice. The results suggest that the concurrent administration of racemic (i.e. dl-) MPH with aripiprazole significantly increased the plasma concentrations of both total MPH as well as the less active l-isomer. The ratio of d-MPH and l-MPH plasma concentrations was significantly decreased in the mice treated with aripiprazole compared to the control animals, indicating an overall decrease of CES1 catalytic activity in aripiprazole treated animals. Additionally, a quantitative structure-activity relationship based analysis identified a number of structural similarities of CES1 inhibitors. In conclusion, drug-drug interactions with MPH are likely mediated via CES1 inhibition as a result of concomitant drug therapies. CES1 inhibition represents an overlooked and little studied source of variability in MPH disposition, tolerability, and response.
机译:设计并进行了一系列研究,以探索人类主要的肝水解酶羧酸酯酶1(hCES1)作为多种药物抑制代谢的目标的潜力。当代谢抑制剂与给定酶的已知或可疑底物组合时,存在不利的药物相互作用的风险。在本报告中,已通过多种常规处方药物将高表达的肝酶hCES1作为代谢抑制的潜在目标进行了检查。尽管hCES1在许多化合物的代谢和解毒中起着作用,但很少对此进行评估。选择抗精神病药物哌醋甲酯(MPH)作为hCES1选择性底物。使用先前开发的细胞系进行了体外研究,该细胞系以对硝基苯乙酸酯和d-MPH作为已知底物过量表达hCES1。阿立哌唑,奋乃静,硫代达嗪和氟西汀被确定为有效的hCES1抑制剂。一项补充性动物研究随后进行了体外筛选研究,以进一步评估阿立哌唑对FVB小鼠CES1活性的抑制作用。结果表明,与阿立哌唑同时施用外消旋(即dl-)MPH与阿立哌唑一起显着增加了总MPH以及活性较低的I-异构体的血浆浓度。与对照动物相比,在用阿立哌唑治疗的小鼠中d-MPH和1-MPH血浆浓度的比率显着降低,表明在阿立哌唑治疗的动物中CES1催化活性总体下降。此外,基于定量构效关系的分析确定了CES1抑制剂的许多结构相似性。总之,伴随药物治疗,与MPH的药物相互作用可能是通过CES1抑制来介导的。 CES1抑制作用代表了MPH处置,耐受性和反应变异性的一个被忽略且很少研究的来源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号